Skip to content
Therapy But Better – Lifestyle
Author:
4Bio Capital
4BIO Capital leads $60M Series A financing of Oyster Therapeutics (formerly Kesmalea Therapeutics) to advance next-generation targeted protein degraders for Alzheimer’s and other neurodegenerative diseases
November 10, 2026
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
September 29, 2026
4BIO Capital Leads $33M Seed for Cloverleaf Bio’s RNA Cancer Therapeutics
September 8, 2026